Discover
NRSN
NeuroSense Therapeutics Ltd.
0.72
2 x 0.50
2 x 0.94
bid
ask
+
0.00
0.42%
2 @ 04:00 PM
0.72 +0.00 (0.00%)
| Ytd | -5.98% | |
| 1y | -61.95% |
0.71
day range
0.74
0.63
52 week range
2.19
| Open | 0.72 | Prev Close | 0.72 | Low | 0.71 | High | 0.74 | Mkt Cap | 26.10M |
| Vol | 91.26K | Avg Vol | 163.58K | EPS | -0.44 | P/E | N/A | Forward P/E | -2.27 |
| Beta | 1.56 | Short Ratio | 2.01 | Inst. Own | 0.97% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-08 | 50-d Avg | 0.79 | 200-d Avg | 0.93 | 1yr Est | 7.50 |
NRSN News
gurufocus.com
NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction
NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction
benzinga.com
NeuroSense Therapeutics Announces Its Phase 2B PARADIGM Study Of PrimeC In Amyotrophic Lateral Scler
First randomized, double-blind, placebo-controlled trial to demonstrate treatment-associated reducti
prnewswire.com
NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction
First randomized, double-blind, placebo-controlled trial to demonstrate treatment-associated reducti
benzinga.com
NeuroSense Therapeutics Announces Data From Its Phase 2 RoAD Trial Of PrimeC In Alzheimer's Disease
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnol
prnewswire.com
NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in
PrimeC was associated with changes across multiple biomarkers spanning key neurodegenerative disease
benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga.com
NeuroSense Therapeutics Secures Japanese Patent 7857044 Covering Its Lead Drug Candidate For Treatme
Patent Protection Extends Through 2042 following recent U.S., Australia and Brazil patentsCAMBRIDGE,
benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session